Bita Sahaf
YOU?
Author Swipe
View article: Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy
Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy Open
Introduction: Circulating tumor DNA (ctDNA)-based measurable residual disease (MRD) assessment is a promising noninvasive biomarker to guide treatment response and surveillance in Large B-cell lymphoma (LBCL). While PET-CT surveillance rem…
View article: Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study Open
Background Axicabtagene ciloleucel(axi-cel) has improved outcomes in relapsed or refractory large B-cell lymphoma(r/rLBCL); however, more than half of patients(pts) experience disease progression or death especially among pts with elevated…
View article: Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL Open
Background: Adults with high-risk (HR), relapsed/refractory (r/r) B-ALL who receive CAR-T often require consolidative allogeneic HCT to achieve long-term remission. Emerging data suggests that adult B-ALL patients (pts) with prior HCT have…
View article: BIOM-107. EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING
BIOM-107. EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING Open
INTRODUCTION Chimeric antigen receptor (CAR) T-cell therapy efficacy continues to improve in solid tumors, including in glioblastoma (GBM). B7-H3 (CD276) is an attractive tumor-associated antigen expressed in glioblastoma and many other so…
View article: CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA Open
H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal cancers in children and young adults. Our team previously demonstrated efficacy of GD2-targeting chimeric antigen receptor (GD2-CAR) T-cells in preclinical models of DMG …
View article: CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias Open
CD19-directed chimeric antigen receptor T-cell therapy (CAR19) improves survival in patients with relapsed/refractory large B-cell lymphoma (rrLBCL) compared to immunochemotherapy with intent for autologous hematopoietic cell transplantati…
View article: Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy Open
[Figure: see text]
View article: IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies Open
Antigen escape relapse is a major challenge in targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell for B-cell acute lymphoblastic leukemia (B-ALL). To identify tumor-intrinsic factors driving …
View article: Figure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparative analysis of CAR22 transduction rate, vector copy number (VCN) and T cell subset in CAR22 products between patients who experienced disease progression (PD) within 90 days versus more than 90 days after CAR19 therapy (A) Patient…
View article: Table S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CAR22 product release criteria
View article: Table S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Key reagents and resources
View article: Figure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparative analysis of Comparative analysis of T cell subsets of CD4/CD8 enrichment material during CAR22 manufacturing process. (A) CD4+ and (B) CD8+ T cells.
View article: Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Hemogram analysis prior to leukapheresis for CAR22
View article: Figure S11 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S11 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CAR22 construction
View article: Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparison of CAR19 transgene level, CAR22 product characteristic and cell kinetics across different CAR19 co-stimulatory domain
View article: Figure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparative analysis of exhaustion markers expression of CD4/CD8 enrichment material during CAR22 manufacturing process Expression of exhaustion markers, including CD39, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1…
View article: Table S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparison of CRS, ICANS, and IEC-HS between different leukapheresis interval groups, CAR19 transgene level, and CAR22 product transduction rate cut off by median
View article: Figure S9 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S9 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Cytopenia within 28 days following CAR22 infusion in early and late groups. (A) The nadir white blood cell count, hemoglobin levela and platelet count were comparable between early and late groups. (B) Similar administration of filgrastim …
View article: Table S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CAR T-cell surveillance methods and time points of the two cohorts
View article: Data from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Data from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Patients with large B-cell lymphoma that progresses after anti–CD19 chimeric antigen receptor (CAR) T-cell (CAR19) therapy have poor outcomes. Subsequent CAR T-cell therapy shows promise, but the impact of residual CAR19 and early relapse …
View article: Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Quantifiable CAR19 transgene levels in leukapheresis material and CAR22 products, and their correlation with CAR22 complete response (CR) rate and survival outcomes. (A) The CR rate is similar between patients with and without quantifiable…
View article: Table S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Cohort 2: Patient demographics upon receiving CAR19 or CAR22 therapies
View article: Table S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Sensitivity analysis for handling residual CAR19 qPCR data below limit of quantification (LOQ) in leukapheresis material
View article: Figure S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CD39 expression on CD4+ and CD8+ CAR22, stratified by median expression levels (High/Low) or using a 20% cutoff, and its correlation with CAR22 expansion as measured by flow cytometry and qPCR, treatment response, and survival outcomes. (A…
View article: Figure S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Linear regression analysis of CAR22 transduction efficiency, vector copy number (VCN) and T cell subsets in CD4/CD8 enrichment material and CAR22 product (A) Linear regression of CAR22 transduction efficiency versus T cell subsets in CD4/C…
View article: Figure S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Maximal expansion (CMax) and area under the curve from day 0 to 28 (AUC0-28) of CAR22 post-infusion, as assessed by flow cytometry (A) and qPCR (B), in early and late groups patients
View article: Figure S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
The CAR T-cell maximal expansion (CMax) and area under the curve from day 0 to 28 (AUC0-28) for CAR19 and CAR22 following CAR19 or CAR22 infusion in the same patient. (A) Analysis by flow cytometry. (B) Analysis by qPCR assay. No statistic…